PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.

Abstract Androgen deprivation therapy (ADT) is a mainstay of treatment for advanced prostate cancer. Several studies have reported an association between ADT and an increase in cardiovascular events, especially in those receiving gonadotropin-releasing hormone (GnRH) agonists compared to GnRH antagonists. We review the body of literature reporting the association of ADT and cardiovascular morbidity, and discuss the proposed mechanism of cardiovascular disease due to ADT including metabolic changes that may promote atherosclerosis and local hormonal effects that may increase plaque rupture and thrombosis.
PMID
Related Publications

Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.

Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists.

A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.

The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK.

Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?.

Authors

Mayor MeshTerms
Keywords

Androgen deprivation

Cardiovascular disease

Degarelix

Gonadotropin-releasing hormone agonist

Gonadotropin-releasing hormone antagonist

Journal Title current urology reports
Publication Year Start




PMID- 28417429
OWN - NLM
STAT- In-Process
DA  - 20170418
LR  - 20170418
IS  - 1534-6285 (Electronic)
IS  - 1527-2737 (Linking)
VI  - 18
IP  - 6
DP  - 2017 Jun
TI  - Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing
      Cardiovascular Disease.
PG  - 41
LID - 10.1007/s11934-017-0688-5 [doi]
AB  - PURPOSE OF REVIEW: Androgen deprivation therapy (ADT) is a mainstay of treatment 
      for advanced prostate cancer. Several studies have reported an association
      between ADT and an increase in cardiovascular events, especially in those
      receiving gonadotropin-releasing hormone (GnRH) agonists compared to GnRH
      antagonists. We review the body of literature reporting the association of ADT
      and cardiovascular morbidity, and discuss the proposed mechanism of
      cardiovascular disease due to ADT including metabolic changes that may promote
      atherosclerosis and local hormonal effects that may increase plaque rupture and
      thrombosis. RECENT FINDINGS: GnRH agonists appear to increase the risk of
      cardiovascular morbidity by 20-25% in men on these agents compared those who do
      not receive ADT. GnRH antagonists may appear to have halve this risk while
      improving PSA progression-free survival. GnRH antagonists may be superior to GnRH
      agonists for patients with significant cardiovascular disease, significant
      metastatic disease burden, or severe lower urinary tract symptoms.
FAU - Greiman, Alyssa K
AU  - Greiman AK
AD  - Department of Urology, Medical University of South Carolina, 96 Jonathan Lucas
      St., CSB 644, Charleston, SC, USA. [email protected]
FAU - Keane, Thomas E
AU  - Keane TE
AD  - Department of Urology, Medical University of South Carolina, 96 Jonathan Lucas
      St., CSB 644, Charleston, SC, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Urol Rep
JT  - Current urology reports
JID - 100900943
OTO - NOTNLM
OT  - Androgen deprivation
OT  - Cardiovascular disease
OT  - Degarelix
OT  - Gonadotropin-releasing hormone agonist
OT  - Gonadotropin-releasing hormone antagonist
EDAT- 2017/04/19 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/04/19 06:00
AID - 10.1007/s11934-017-0688-5 [doi]
AID - 10.1007/s11934-017-0688-5 [pii]
PST - ppublish
SO  - Curr Urol Rep. 2017 Jun;18(6):41. doi: 10.1007/s11934-017-0688-5.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>